Last reviewed · How we verify
HMB plus Vitamin D
HMB plus Vitamin D is a Small molecule drug developed by Metabolic Technologies Inc.. It is currently in Phase 1 development. Also known as: HMB (Calcium beta-hydroxy-beta-methylbutyrate), Vitamin D (Cholecalciferol).
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | HMB plus Vitamin D |
|---|---|
| Also known as | HMB (Calcium beta-hydroxy-beta-methylbutyrate), Vitamin D (Cholecalciferol) |
| Sponsor | Metabolic Technologies Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle Mass and Function in Female Athletes (PHASE2)
- This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65. (NA)
- Precision Medicine and Physical Function (NA)
- Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis (NA)
- LIver FRAilty Management IN Cirrhosis (LIFRAMIN) (NA)
- Preserving Physical Function in Older Adults With Cancer: Impact of an Optimizing Nutrition Intervention Applied Before and After Surgery (NA)
- Essential Amino Acid Supplementation for Femoral Fragility Fractures (PHASE2)
- Standard vs Intensive Rehabilitation and Nutrition Regimen for Inpatients at the ICU (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HMB plus Vitamin D CI brief — competitive landscape report
- HMB plus Vitamin D updates RSS · CI watch RSS
- Metabolic Technologies Inc. portfolio CI
Frequently asked questions about HMB plus Vitamin D
What is HMB plus Vitamin D?
Who makes HMB plus Vitamin D?
Is HMB plus Vitamin D also known as anything else?
What development phase is HMB plus Vitamin D in?
Related
- Manufacturer: Metabolic Technologies Inc. — full pipeline
- Also known as: HMB (Calcium beta-hydroxy-beta-methylbutyrate), Vitamin D (Cholecalciferol)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing